Associations Between Hormonal Biomarkers and Preterm Infant Health and Development During the First 2 Years After Birth.


Journal

Biological research for nursing
ISSN: 1552-4175
Titre abrégé: Biol Res Nurs
Pays: United States
ID NLM: 9815758

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 24 7 2020
medline: 22 7 2021
entrez: 24 7 2020
Statut: ppublish

Résumé

Testosterone levels have been used to examine infant boys' vulnerability to health and developmental problems, following the general theories of gender differences and the theory of extreme male brain of autism. As testosterone is a representative androgen hormone and is higher in preterm than full-term infants, we used this steroid to determine if hypothalamic pituitary hormones, testosterone, and cortisol, were related to physical growth, health, and development of very-low-birthweight (VLBW, BW < 1,500 g) infants. For this comparative longitudinal study, 40 VLBW infants were recruited from a neonatal intensive care unit of a tertiary medical center. Data were collected from medical record reviews, questionnaires, and assessments of infant development at 6, 12, and 24 months. We collected saliva at the three time points and measured hormones using enzyme-immunoassays. General and generalized mixed models showed that a 1pg/ml increment of testosterone was related to a -0.42% decrease in body weight, a -0.18% decrease in length, and a -0.10% decrease in head circumference. Cortisol levels were not associated with any outcome variable. The interactions between testosterone and time on physical growth and socioemotional development also occurred. Elevated testosterone levels can be a biological risk factor for poor infant growth and development. Theories about the effects of elevated prenatal testosterone could be useful in predicting health and developmental outcomes among VLBW infants. Research beyond the first 2 years will be needed as infants show more socioemotional and behavioral problems as they grow older.

Sections du résumé

BACKGROUND
Testosterone levels have been used to examine infant boys' vulnerability to health and developmental problems, following the general theories of gender differences and the theory of extreme male brain of autism.
OBJECTIVES
As testosterone is a representative androgen hormone and is higher in preterm than full-term infants, we used this steroid to determine if hypothalamic pituitary hormones, testosterone, and cortisol, were related to physical growth, health, and development of very-low-birthweight (VLBW, BW < 1,500 g) infants.
METHOD
For this comparative longitudinal study, 40 VLBW infants were recruited from a neonatal intensive care unit of a tertiary medical center. Data were collected from medical record reviews, questionnaires, and assessments of infant development at 6, 12, and 24 months. We collected saliva at the three time points and measured hormones using enzyme-immunoassays.
RESULTS
General and generalized mixed models showed that a 1pg/ml increment of testosterone was related to a -0.42% decrease in body weight, a -0.18% decrease in length, and a -0.10% decrease in head circumference. Cortisol levels were not associated with any outcome variable. The interactions between testosterone and time on physical growth and socioemotional development also occurred.
DISCUSSION
Elevated testosterone levels can be a biological risk factor for poor infant growth and development. Theories about the effects of elevated prenatal testosterone could be useful in predicting health and developmental outcomes among VLBW infants. Research beyond the first 2 years will be needed as infants show more socioemotional and behavioral problems as they grow older.

Identifiants

pubmed: 32700638
doi: 10.1177/1099800420942893
pmc: PMC8264856
doi:

Substances chimiques

Biomarkers 0
Testosterone 3XMK78S47O
Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

188-197

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD076871
Pays : United States

Références

Int J Dev Neurosci. 2011 Jun;29(4):381-8
pubmed: 21473905
J Psychiatry Neurosci. 2005 Sep;30(5):315-8
pubmed: 16151535
NCHS Data Brief. 2018 Jun;(312):1-8
pubmed: 30044213
Am J Physiol Endocrinol Metab. 2004 Nov;287(5):E863-70
pubmed: 15238353
J Clin Endocrinol Metab. 2011 Jan;96(1):98-105
pubmed: 20881260
J Clin Med. 2019 Nov 19;8(11):
pubmed: 31752272
Acad Emerg Med. 2017 Apr;24(4):458-466
pubmed: 27859997
Biol Psychol. 2013 Feb;92(2):212-5
pubmed: 23153707
Psychoneuroendocrinology. 2019 Apr;102:225-235
pubmed: 30590340
Front Psychol. 2017 Apr 07;8:456
pubmed: 28439244
J Neuroendocrinol. 2008 Apr;20(4):489-96
pubmed: 18266948
Clin Biochem. 2014 Oct;47(15):101-8
pubmed: 24927648
Clin Chem Lab Med. 2017 Aug 28;55(9):1315-1323
pubmed: 28076306
Sci Rep. 2017 Jun 28;7(1):4332
pubmed: 28659579
Trends Cogn Sci. 2002 Jun 1;6(6):248-254
pubmed: 12039606
Infant Ment Health J. 2016 Mar-Apr;37(2):125-39
pubmed: 26939829
Biol Psychol. 2013 Sep;94(1):152-9
pubmed: 23727253
Front Psychol. 2014 Jul 29;5:781
pubmed: 25120503
Acta Paediatr. 2006 Oct;95(10):1239-48
pubmed: 16982497
Biol Res Nurs. 2019 Mar;21(2):210-223
pubmed: 30654634
Arch Womens Ment Health. 2011 Feb;14(1):33-41
pubmed: 20872154
Rev Chil Pediatr. 2019 Jun;90(3):275-282
pubmed: 31344187
Mol Autism. 2016 Feb 17;7:15
pubmed: 26893820
Biol Res Nurs. 2014 Jan;16(1):72-82
pubmed: 23034538
J Child Psychol Psychiatry. 2012 Jul;53(7):726-34
pubmed: 22276678
Pediatr Crit Care Med. 2015 May;16(4):e101-6
pubmed: 25647239
J Endocrinol. 2014 May 12;221(2):347-62
pubmed: 24594617
Nurs Res. 2017 Sep/Oct;66(5):350-358
pubmed: 28661908
Psychoneuroendocrinology. 2019 Apr;102:204-211
pubmed: 30583244
PeerJ. 2019 Feb 7;7:e6368
pubmed: 30746307
Eur J Psychotraumatol. 2015 Mar 11;6:25216
pubmed: 25765534
J Pediatr. 2018 Dec;203:301-308
pubmed: 30197200
J Neurodev Disord. 2012 Oct 30;4(1):25
pubmed: 23110806
Brain Lang. 2015 Feb;141:70-6
pubmed: 25540858
Early Hum Dev. 2012 Oct;88(10):789-95
pubmed: 22633533
Steroids. 2018 Oct;138:26-34
pubmed: 29864449
Horm Res Paediatr. 2017;87(2):111-115
pubmed: 28073108

Auteurs

June Cho (J)

School of Nursing, University of Nevada, Las Vegas, NV, USA.

Lung-Chang Chien (LC)

Epidemiology and Biostatistics program, Department of Environmental and Occupational Health, School of Public Health, University of Nevada Las Vegas, NV, USA.

Diane Holditch-Davis (D)

Marcus E. Hobbs Professor Emeritus, School of Nursing, 3065Duke University, DUMC, Durham, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH